Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:CKPTNASDAQ:DYNNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$57.27-3.1%$66.62$52.50▼$77.00$1.24B0.56301,573 shs358,437 shsCKPTCheckpoint Therapeutics$4.17-0.2%$4.07$1.75▼$4.50$349.30M1.181.27 million shs3.21 million shsDYNDyne Therapeutics$11.90+1.2%$10.34$6.36▼$47.45$1.35B1.191.64 million shs1.74 million shsVERAVera Therapeutics$19.63-3.7%$22.90$18.53▼$51.61$1.25B1.28781,991 shs658,402 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-2.57%-2.14%-13.12%-1.09%-4.26%CKPTCheckpoint Therapeutics+0.48%+0.72%+3.47%+31.45%+110.05%DYNDyne Therapeutics-4.70%+0.51%+26.05%-15.94%-63.96%VERAVera Therapeutics-4.00%-3.78%-3.41%-31.14%-48.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals4.8207 of 5 stars4.53.00.03.33.93.31.3CKPTCheckpoint Therapeutics2.2083 of 5 stars1.24.00.04.22.10.80.0DYNDyne Therapeutics3.7239 of 5 stars4.52.00.00.04.14.20.0VERAVera Therapeutics3.3548 of 5 stars4.62.00.00.04.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1339.91% UpsideCKPTCheckpoint Therapeutics 2.33Hold$4.333.92% UpsideDYNDyne Therapeutics 3.07Buy$47.25297.06% UpsideVERAVera Therapeutics 3.10Buy$63.33222.64% UpsideCurrent Analyst Ratings BreakdownLatest CKPT, VERA, DYN, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.003/31/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.80 ➝ $4.803/21/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$674.07M1.84$6.34 per share9.03$21.13 per share2.71CKPTCheckpoint Therapeutics$41K8,519.41N/AN/A($0.47) per share-8.87DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.27N/A13.60N/A-1.28%15.87%6.88%8/5/2025 (Estimated)CKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%N/ADYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%N/AVERAVera Therapeutics-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%N/ALatest CKPT, VERA, DYN, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/A2/26/2025Q4 2024VERAVera Therapeutics-$0.83-$0.72+$0.11-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ACKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97CKPTCheckpoint TherapeuticsN/A0.290.29DYNDyne TherapeuticsN/A17.0217.02VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%CKPTCheckpoint Therapeutics22.00%DYNDyne Therapeutics96.68%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%CKPTCheckpoint Therapeutics2.10%DYNDyne Therapeutics20.77%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million18.36 millionOptionableCKPTCheckpoint Therapeutics1083.76 million47.81 millionOptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableVERAVera Therapeutics4063.75 million49.58 millionOptionableCKPT, VERA, DYN, and ANIP HeadlinesRecent News About These CompaniesWoodline Partners LP Acquires 201,573 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 22 at 6:18 AM | marketbeat.comMarker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming WebcastMay 21 at 7:23 PM | nasdaq.comVestal Point Capital LP Acquires Shares of 1,075,000 Vera Therapeutics, Inc. (NASDAQ:VERA)May 21 at 8:14 AM | marketbeat.comThornburg Investment Management Inc. Acquires 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 21 at 5:59 AM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Point72 Asset Management L.P.May 21 at 5:27 AM | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)May 21 at 4:03 AM | marketbeat.comMPM Bioimpact LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Paradigm Biocapital Advisors LPMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Nicholas Investment Partners LPMay 16, 2025 | marketbeat.comEquities Analysts Offer Predictions for VERA FY2025 EarningsMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Holdings Raised by Deutsche Bank AGMay 16, 2025 | marketbeat.comNorthern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)May 16, 2025 | marketbeat.comVera Therapeutics: Huge Catalyst Upcoming For Kidney Disease DrugMay 15, 2025 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comFY2025 EPS Forecast for Vera Therapeutics Reduced by AnalystMay 15, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Position Boosted by Integral Health Asset Management LLCMay 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Cuts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 14, 2025 | marketbeat.comVera Therapeutics price target lowered to $55 from $60 at ScotiabankMay 12, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Releases Earnings Results, Misses Estimates By $0.06 EPSMay 12, 2025 | marketbeat.comAlgert Global LLC Acquires 15,386 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 12, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for VERA EarningsMay 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative GainsCan IBM’s Q1 Earnings Spark a Breakout for the Stock?By Jeffrey Neal Johnson | April 23, 2025View Can IBM’s Q1 Earnings Spark a Breakout for the Stock?Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostBy Leo Miller | May 7, 2025View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostCKPT, VERA, DYN, and ANIP Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$57.27 -1.81 (-3.06%) Closing price 04:00 PM EasternExtended Trading$57.28 +0.01 (+0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Checkpoint Therapeutics NASDAQ:CKPT$4.17 -0.01 (-0.24%) Closing price 04:00 PM EasternExtended Trading$4.17 0.00 (0.00%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Dyne Therapeutics NASDAQ:DYN$11.90 +0.14 (+1.19%) Closing price 04:00 PM EasternExtended Trading$12.08 +0.19 (+1.55%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Vera Therapeutics NASDAQ:VERA$19.63 -0.76 (-3.73%) Closing price 04:00 PM EasternExtended Trading$21.32 +1.70 (+8.63%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
